China Health Resource Begins R&D Efforts with Chengdu University for Tianma

Share Article

China’s leading producer of Dahurian Angelica Root makes plans to offer new line of herbal supplements

“The certification awarded by the government is a big step for CHRI and we will focus our efforts on developing valuable herbal products for the community.”

China Health Resource (OTCBB: CHRI) announced today that it has entered into a long-term cultivation and cooperation agreement with Chengdu University for a new Traditional Chinese Medicine (TCM) product, Tianma. The Company will add this new herb to its current product offering after it was certified by the Chinese government to expand its TCM line last week.

The Company has stepped up cooperative efforts with Chengdu University, a long term research partner and one of the oldest and most established TCM educational institutions in China. These efforts include the domestication, cultivation technology, and extraction of active ingredients from Tianma.

“We will continue to develop and expand the varieties of quality Chinese herbal medicines to offer a wider range of herbs to our customers,” said Jiayin Wang, CEO. “The certification awarded by the government is a big step for CHRI and we will focus our efforts on developing valuable herbal products for the community.”

The cooperative R&D plans will focus on ensuring consistent quality in the planting process and in the development of high-quality Tianma products. The Tianma product is one of the more expensive TCM products in today’s market and is used to treat headaches, dizziness, numbness, convulsions in children, and epilepsy.
CHRI will leverage its success in the Dahurian Angelica Root (DAR) market and begin development of a wider variety of valuable Chinese herbal medicines while continuing to improve its DAR production standards.

About CHRI
China Health Resource Inc. engages in the development, manufacturing, processing, marketing and sale of Dahurian Angelica Root (DAR) and related products in the People's Republic of China. DAR, which is also known as “Bai Zhi” in Mandarin Chinese, is an herb that is employed as an ingredient in medicine, cosmetics and food, as well as used in TCM for the treatment of pain, swelling and pustule. The company's DAR-related products include the Bailing Capsule, Yisheng Capsule, Kimchee-Mate and Fragrant Bag, all of which are sold through regional distributors. The company was founded in 2001 and is based in Suining.

About Chengdu University of Traditional Chinese Medicine
Chengdu University of Traditional Chinese Medicine is one of the first educational institutions to focus completely on Traditional Chinese Medicine. The university awards Chinese medicine doctorates, master’s degrees and offers post-doctoral research opportunities with the Ministry of Health and Ministry of Education.

Certain statements found other than historical facts in this document regarding financial matters other than historical facts, and statements of our expectations, intentions, plans and beliefs, constitute "forward-looking statements" within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, as amended, that are subject to certain events, risks and uncertainties that may be outside our control. The words "believe", "expect", "anticipate", "optimistic", "intend", "will", and similar expressions identify forward-looking statements. The company intends that such proclamations about future expectations, including future revenues and earnings, future business expansion plans, and all other forward-looking statements be subject to the safe harbors created thereby. Management retains broad discretion with regard to all future business operations of the Company. Since these statements involve risks and uncertainties and are subject to change at any time, the company's actual results may differ materially from expected results. These and other risks and uncertainties related to our business are described in greater detail in our filings with the Commission. The foregoing information should be read in conjunction with these filings. We disclaim any intention or obligation to update or revise any forward-looking statements. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date on which they are made.

For more information, please contact: China Health Resource, Inc., 343 Suining Zhong Road, Suining, Sichuan, P.R.China, . Tel: +86-825-239-1788, Web Site:


Share article on social media or email:

View article via:

Pdf Print

Contact Author

Rebecca Binny-Hallmark

+1 (323) 403 3829
Email >
Visit website